CroíValve, a Dublin, Ireland-based medical device company focused on the development of a novel transcatheter device for the treatment of tricuspid regurgitation, raised $16M in equity funding.
The round was led by MedTech & Irrus Syndicates, included participation from all current investors, Ascentifi, Furthr, Broadview Ventures, Atlantic Bridge University Fund, Enterprise Ireland, Elkstone & SOSV, along with a new investor, IAG Capital Partners.
The company intends to use the funds to further enhance the TANDEM II Early Feasibility Study, an FDA-approved, prospective, multicenter study to evaluate the safety and performance of the DUO™ System in patients with severe or greater symptomatic tricuspid regurgitation (TR).
Led by CEO Lucy O’Keeffe, CroíValve is a clinical stage medical device company focused on the development of a novel transcatheter device for the treatment of tricuspid regurgitation with research, development and operations based in Ireland and clinical and regulatory based in the United States.
The DUO™ System is a novel transcatheter heart valve that works in tandem with the native tricuspid valve to restore valve function while leaving the patient’s right heart and native valve apparatus untouched through an innovative anchoring mechanism. Designed to treat a broad patient population, the DUO™ System accommodates the heterogeneity of patient anatomies while avoiding contact with critical structures in the right heart which could lead to complications. The DUO™ System is also designed to enable a straightforward procedure and reduce the procedural complexity seen with other devices.
The company also added Daniel Gottlieb, a Director with Broadview Ventures, to its Board of Directors
FinSMEs
07/08/2024